Abstract
Despite extensive research in squamous cell carcinoma of thehead and neck (SCCHN), the epidermal growth factor receptor(EGFR)remainstheonlynonchemotherapeuticmoleculartargetthathas been successfully translated into a biologic therapy with clinicalbenefit. Targeting this transmembrane tyrosine kinase growth factorreceptor in SCCHN is an attractive and rational strategy given thatmore than 90% of these tumors overexpress EGFR. The potentialvalue of EGFR as a therapeutic target is also supported by the obser-vation that poor prognostic outcomes have been correlated with in-creased EGFR protein expression or
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
